Cumulative incidence of cause-specific death at 5 years stratified by protocol
| Cause . | Earlier cohorts . | Recent cohorts . | Recent vs earlier . | |||
|---|---|---|---|---|---|---|
| AML97 (N = 50), cumulative incidence (95% CI), % . | Total Therapy 13/Total Therapy 14 (N = 57), cumulative incidence (95% CI), % . | AML02 (N = 46), cumulative incidence (95% CI), % . | Total Therapy 15 (N = 37), cumulative incidence (95% CI), % . | Hazard ratio (CI) . | P . | |
| GVHD | 4.0 (0.7-12.2) | 10.8 (4.35-20.6) | 3.0 (0.2-13.5) | 5.5 (0.98-16.2) | 0.38 (0.1-1.4) | .16 |
| Infection | 22.0 (11.7-34.3) | 10.8 (4.24-20.8) | 4.4 (0.28-18.6) | 2.9 (0.21-13.1) | 0.12 (0.03-0.5) | .005 |
| Regimen toxicity | 12.0 (4.7-22.9) | 32.2 (20.4-44.6) | 6.6 (1.7-16.3) | 9.4 (2.2-23) | 0.25 (0.1-0.6) | .002 |
| Relapse | 26.0 (14.7-38.8) | 18.1 (9.1-29.3) | 12.0 (4.3-23.9) | 17.5 (7.0-32) | 0.40 (0.2-0.8) | .013 |
| Cause . | Earlier cohorts . | Recent cohorts . | Recent vs earlier . | |||
|---|---|---|---|---|---|---|
| AML97 (N = 50), cumulative incidence (95% CI), % . | Total Therapy 13/Total Therapy 14 (N = 57), cumulative incidence (95% CI), % . | AML02 (N = 46), cumulative incidence (95% CI), % . | Total Therapy 15 (N = 37), cumulative incidence (95% CI), % . | Hazard ratio (CI) . | P . | |
| GVHD | 4.0 (0.7-12.2) | 10.8 (4.35-20.6) | 3.0 (0.2-13.5) | 5.5 (0.98-16.2) | 0.38 (0.1-1.4) | .16 |
| Infection | 22.0 (11.7-34.3) | 10.8 (4.24-20.8) | 4.4 (0.28-18.6) | 2.9 (0.21-13.1) | 0.12 (0.03-0.5) | .005 |
| Regimen toxicity | 12.0 (4.7-22.9) | 32.2 (20.4-44.6) | 6.6 (1.7-16.3) | 9.4 (2.2-23) | 0.25 (0.1-0.6) | .002 |
| Relapse | 26.0 (14.7-38.8) | 18.1 (9.1-29.3) | 12.0 (4.3-23.9) | 17.5 (7.0-32) | 0.40 (0.2-0.8) | .013 |